New York, April 24, 2026, 08:10 EDT
- Regeneron gained 2.6% Thursday, lifted by a U.S. drug-pricing deal and news that its just-approved Otarmeni gene therapy will be provided free in the U.S.
- Raymond James is sticking with its Outperform call and $910 price target. Cantor Fitzgerald, for its part, keeps the Overweight rating and $800 target.
- Regeneron shares settled at $766.02—higher on the week and month, though the stock remains down for the year. With earnings due April 29, the valuation question isn’t going away.
Regeneron Pharmaceuticals caught Wall Street’s attention again—investors now have more to chew on after a U.S. drug-pricing agreement, a unique FDA approval, and new backing from analysts, all ahead of next week’s earnings report.
Timing is key here. Regeneron’s first-quarter numbers are set for release April 29, before U.S. markets open, and that recent jump in the stock has only intensified what’s already been a prominent debate in recent analyst notes: can the pipeline and potential policy tailwinds keep fueling gains after the last six months’ rally?
Raymond James is sticking with its Outperform call and $910 price target for Regeneron after the company’s investor update highlighting its C5 complement program, which includes the drugs cemdisiran and pozelimab. The analysts flagged key fourth-quarter 2026 events: an FDA decision in generalized myasthenia gravis, and upcoming data readouts across other indications.
Cantor Fitzgerald stuck with its Overweight rating and left its $800 price target unchanged, according to GuruFocus. MarketBeat pointed out that Cantor’s target suggested a potential upside of roughly 4.4% from the previous close. The overall analyst consensus? Moderate Buy.
Regeneron’s valuation isn’t straightforward. The stock wrapped up recently at $766.02, according to Simply Wall St, putting on 2.7% over the past week and 3.3% for the month, but still down 1.3% for the year so far. Their discounted cash flow model, which looks at future projected cash flows, pointed to the shares being undervalued by its metrics. On the other hand, the price-to-earnings approach placed Regeneron right at the biotech industry average, and actually below its direct peer group.
Washington delivered the real shock: Regeneron announced a deal with the U.S. government to cut Medicaid prices, benchmarking them to those in other developed nations. The company also agreed to peg future U.S. drug prices to international levels and to offer Praluent on TrumpRx.gov at a most-favored-nation price—meaning the lowest price paid by comparable wealthy countries.
Leonard Schleifer, the chief executive, argued that U.S. patients and taxpayers have “shouldered a disproportionate share” of the costs tied to biotech innovation. He added that the agreement has the potential to narrow the gap in global prices, without undercutting innovation. Regeneron Pharmaceuticals Inc.
Regeneron announced that Otarmeni, its gene therapy targeting severe OTOF-related genetic hearing loss, picked up accelerated approval from the FDA and will be offered at no cost in the U.S. According to the FDA, this marks the first approval for a dual adeno-associated virus vector-based gene therapy for this indication. In clinical trials, 80% of patients who could be evaluated showed hearing improvements.
Eliot Shearer, otolaryngologist at Boston Children’s Hospital and investigator for the CHORD trial, described the approval as “a new era” for treating genetic hearing loss. Regeneron estimates that roughly 50 U.S. newborns each year are affected by OTOF-related hearing loss. Regeneron Pharmaceuticals Inc.
Dupixent, the company’s drug developed alongside Sanofi, picked up another regulator’s nod this week. The FDA signed off on its use for kids aged two to 11 battling chronic spontaneous urticaria, a skin disorder known for persistent hives and intense itching. “Limited treatment options” have left these young patients underserved, Sanofi’s Alyssa Johnsen noted. Sanofi
There’s a political edge to the competition as well. Reuters noted that Pfizer, Eli Lilly and Amgen had previously accepted price reductions during the Trump-era negotiations. Regeneron, for its part, was the last holdout among the 17 pharma firms in that batch of talks, according to Reuters.
Risks remain. AP reported that the complete terms of the pricing agreements haven’t been disclosed. The FDA noted its backing for Otarmeni could hinge on lasting hearing gains and confirmed benefits for speech and quality of life. Over at Regeneron, some legacy units are still under strain—Eylea, for example, continues to feel the pinch from rivals.
Investors are looking at a less tangled picture than last week, though far from clarity. Pipeline catalysts remain front and center for analysts; shares have bounced back somewhat. The company dropped a batch of regulatory and policy headlines just ahead of earnings. Next up: first-quarter results, which will have to deliver if these latest moves are going to matter beyond a single trading session.
